Compare Natera Inc. Common Stock (NTRA) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Zeta Global Holdings Corp — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Zeta Global Holdings Corp trades at $31.87 (market cap $8.48B). The key difference: Natera Inc. Common Stock is far larger — about 6.7× Zeta Global Holdings Corp's market cap, and Zeta Global Holdings Corp is more actively traded (4,868,041 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Zeta Global Holdings Corp for 19 Days on average.
| NTRA | ZETA | |
|---|---|---|
Market Cap | $57.03B | $8.48B |
Volume | 1,131,157 | 4,868,041 |
Sector | Health | Technology |
52-Week High | $425.64 | $33.80 |
52-Week Low | $179.42 | $14.55 |
Typical Hold Time | 0 Days | 19 Days |
Enterprise Value | $56.18B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Zeta Global (ZETA) trades at $33.80, up 0.87% today, showing strong momentum with seven consecutive quarters of earnings beats. The stock exhibits a bullish technical setup with moving averages supporting the uptrend, though RSI levels suggest potential overbought conditions. Revenue growth accelerated to $1.3 billion in 2025 with improving margins, while analyst consensus remains strongly positive with 76% buy ratings and a $37.09 price target. Recent expansion into the UK market and AI platform adoption continue to drive investor optimism.
ZETA presents a compelling growth story with accelerating revenue and expanding customer base, though negative net margins and elevated valuation multiples warrant caution. The stock's proximity to 52-week highs combined with strong institutional support suggests continued upside potential, but investors should monitor margin improvement and competitive pressures in the AI marketing technology space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
